
Opinion|Videos|March 12, 2024
Efficacy and Safety and Emerging Combinations
Author(s)Robert J. Motzer, MD
Dr. Motzer provides his perspective on emerging efficacy and safety data updates from KEYNOTE-B61, and Nivolumab+Cabozantinib, evaluating combination regimens in nccRCC.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
4
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
5

































